I saw this insulin back at the IDF Congress back in October, it is taken on a daily basis for some adult Type 2 diabetics. The reason I say "some", is because it seems to be aimed at those Type 2's that are having difficulty ith maintaining their BG's (blood glucose) with the usual prescribed methods. Victoza has been on the market in Europe but has been awaiting approval by FDA, which just occurred yesterday - so this is hot off the press!

The one thing that Victoza (liraglutide) is pushing, is that it is a once a day injection of insulin, rather then its only competitor Byetta that is injected twice a day (currently there is research on a once a week version of Byetta). There have been some problems associated with Byetta though and if you read the link to Victoza it has a few issues too, but what drug these days doesn't?

The thing that was being pushed at the congress about Victoza was that early treatment with Victoza showed excellent reductions in blood glucose (BG) with a low risk of going into low BG (hypoglycaemia). It also was shown to help patients reach the A1C level of 7% or less. As we all know, the lower the A1C in a diabetic, the better our chances are of having less complications with our diabetes later on.

Also, weight loss, again with early treatment, and maintaining the weight was much better and with that weight loss came better blood pressure readings.

NB: More than 4,200 patients taking both Metaformin (2000 mg) and Victoza (either 1.2 mg or 1.8 mg) over a short-term/intermediate-term/long-term, and as well with ongoing trials (in the brochure I had picked up from Novo Nordisk - 26 weeks seems to be the length for much of what the results are based on). Only 2.8% of patients withdrew due to nausea, the most common adverse reaction to using Victoza.